Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
An overview on rare disease research
ICON's Tim Clark and Will Maier examine the key clinical, regulatory, and commercial challenges associated with the development of therapies for the treatment of rare diseases.
-
A conversation with an expert in drug development
Colin Orford, Senior Vice President of Drug Development services at ICON, about finding an effective treatment for COVID-19.
-
Encouraging patient participation in real world studies
Real world data is rapidly becoming the latest frontier for life sciences companies for supporting regulatory filings and conducting drug safety surveillance. ICON experts discuss the critical role of patients and advocacy groups in the June issue of Pharmaceutical Market Europe.
-
The importance of partnering for bioanalytical studies
BioPharm International speaks with ICON's Robert Kernstock about the need for bioanalytical testing programs and regulatory strategies for potential new biologics.
-
Mitigating the impact of COVID-19 on CV trials and participants
A thought leadership article authored by Jack Martin, Mary Jane Geiger and Deirdre Albertson which focuses on navigating cardiovascular clinical trials during COVID-19 by adopting patient-centric technologies to keep patients safe and studies on track. The article is published in PharmaFile Spring 2020 on page 40.
-
Here’s what we have to do to show a coronavirus vaccine works
A article featuring expert commentary from ICON's Cynthia Dukes about the development of a vaccine for COVID-19.
-
Improving access and reimbursement for specialty therapies
As specialty therapies move toward long-term maintenance use and as treatment times grow longer, payers are scrutinising the economic value more closely. ICON experts discuss how clinical development can better satisfy the evidence needs of HTA bodies and payers.
-
While the world waits
ICON's Cindy Dukes considers the best practices for developing a vaccine and treatments for COVID-19.
-
ICON nabs former Optum, FDA and AstraZeneca exec as new chief medical officer
Fierce Biotech reports on ICON's appointment of Dr. Kristen Buck as its new chief medical officer.
-
Company of the Month April 2020: ICON plc’s Q1 figures indicate strong growth
Business & Finance names ICON as 'Company of the Month' for April 2020.
